Sirona Biochem Announces Grant of Stock Options

VANCOUVER, BC--(Marketwired - November 20, 2017) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that it has granted an aggregate of 2,350,000 bonus and incentive stock options to management, independent directors and consultants of the Company. The options, to purchase common shares in the capital of the Company at a price of $0.15 per common share, will be for a period of 10 years for management and 5 years for independent directors and consultants. Periods end November 20, 2027 and November 20, 2022 respectively. The options have been granted under the terms of the Company's stock option plan.

/EINPresswire.com/ -- On behalf of the board of Directors.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.